Biogen Competitors and Similar CompaniesClear all
Biogen's competitors and similar companies include Omega Therapeutics, Cassava Sciences, Fortrea US, Sanofi Genzyme, EMD Serono, Genentech, Novartis, Bayer, Amgen, Gilead Sciences and Regeneron Pharmaceuticals.
 Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Cassava Sciences Cassava Sciences (formerly known as Pain Therapeutics) is a clinical-stage biotechnology company that specializes in drug development. |  Fortrea US Fortrea US (formerly known as Labcorp Drug Development) is a company that specializes in clinical development and patient access solutions. |  Sanofi Genzyme Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. |  EMD Serono EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany. Committed to transforming lives. |  Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. | |||
Founding Date | Founding Date 1978 | Founding Date 2017 | Founding Date 1998 | Founding Date 1968 | Founding Date 1981 | Founding Date N/A | Founding Date 1976 | Founding Date 1996 | Founding Date 1863 | Founding Date 1980 | Founding Date 1987 | Founding Date 1988 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Subsidiary | Type Private | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Cambridge, US HQ | Locations Austin, US HQ | Locations Durham, US HQ | Locations Cambridge, US HQ Macquarie Park, AU Malaga, AU Virginia, AU São Paulo, BR Mississauga, CA Toronto, CA see more | Locations Rockland, US HQ Mississauga, CA Billerica, US | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Vacaville, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | |
Employees | Employees 7,57013% decrease | Employees 60 | Employees 2912% increase | Employees 15,099 | Employees 9,9041% decrease | Employees 1,887 | Employees 17,870 | Employees 76,057 | Employees 94,2454% decrease | Employees 25,200 | Employees 18,0006% increase | Employees 13,9264% increase |
Valuation ($) | Valuation ($) 26.7 b | Valuation ($) 68.4 m | Valuation ($) 1.3 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 27.1 b | Valuation ($) 170.4 b | Valuation ($) 110.5 b | Valuation ($) 102.2 b |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $9.8b (FY, 2023) | Revenue (est.) $3.1m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $5.7b (FY, 2022) | Revenue (est.) €10.4b (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $54.1b (FY, 2023) | Revenue (est.) €47.6b (FY, 2023) | Revenue (est.) $28.2b (FY, 2023) | Revenue (est.) $27.1b (FY, 2023) | Revenue (est.) $13.1b (FY, 2023) |
Cost of goods | Cost of goods $2.5b (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $8.2b (FY, 2023) | Cost of goods €7b (FY, 2023) | Cost of goods $8.5b (FY, 2023) | Cost of goods $6.5b (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit $7.3b (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $47.7b (FY, 2023) | Gross profit €42.1b (FY, 2023) | Gross profit $19.7b (FY, 2023) | Gross profit $20.6b (FY, 2023) | Gross profit N/A |
Net income | Net income $1.2b (FY, 2023) | Net income ($97.4m) (FY, 2023) | Net income ($97.2m) (FY, 2023) | Net income N/A | Net income N/A | Net income N/A | Net income N/A | Net income $9b (FY, 2023) | Net income (€2.9b) (FY, 2023) | Net income $6.7b (FY, 2023) | Net income $5.6b (FY, 2023) | Net income $4b (FY, 2023) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 100 (Nov, 2020) | Countries N/A | Countries N/A | Countries N/A | Countries 83 (FY, 2021) | Countries 100 (FY, 2020) | Countries 35 (FY, 2021) | Countries N/A |
Patents (EU) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A | Patents (EU) 17 (FY, 2020) |
Patents (US) | Patents (US) 21 (FY, 2021) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 605 (Nov, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) 31 (FY, 2020) |
Phase I Trials Products | Phase I Trials Products 10 (Q2, 2022) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 8 (Q2, 2022) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 9 (Q2, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products N/A | Products N/A | Products N/A | Products 25 (Nov, 2020) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A | Products 21 (FY, 2021) | Products 11 (FY, 2022) |
Trademarks | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks 1.5 k (FY, 2021) | Trademarks N/A | Trademarks N/A | Trademarks 20 (FY, 2022) |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 211m | Total funding raised N/A | Total funding raised $ 1.3m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 3.5b | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 53.9m |
For sources of this data, please see the company profile
View Company Profiles
Omega Therapeutics
HQ
Cambridge, US
Employees
60
Omega Therapeutics is an epigenomic medicine company.
View companyCassava Sciences
HQ
Austin, US
Employees
29↑ 12% increase
Cassava Sciences (formerly known as Pain Therapeutics) is a clinical-stage biotechnology company that specializes in drug development.
View companyFortrea US
HQ
Durham, US
Fortrea US (formerly known as Labcorp Drug Development) is a company that specializes in clinical development and patient access solutions.
View companySanofi Genzyme
HQ
Cambridge, US
Sanofi Genzyme (also known as Genzyme Corporation) is a biotech company that specializes in rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology.
View company